Gilead submits hepatitis C drug sofosbuvir for FDA approval

04/9/2013 | American City Business Journals · RTT News

Gilead Sciences filed a new drug application with the FDA for sofosbuvir, an oral nucleotide analogue, to treat chronic hepatitis C virus infection. The firm seeks to use sofosbuvir in combination with existing treatments ribavirin and pegylated interferon in treatment-naive patients with genotype 1, 4, 5 and 6 infection. The drug is expected to be approved by year's end or early next year.

View Full Article in:

American City Business Journals · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN